Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Danny Con
Response
1Department of Medicine, Eastern Health, Melbourne, Victoria, Australia 2Department of Gastroenterology, Austin Hospital, Heidelberg, Victoria, Australia 3Central Clinical School, Monash University, Melbourne, Victoria, Australia 4Department of Gastroenterology, Austin Hospital, Heidelberg, Victoria, Australia 5Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia 6Department of Medicine, University of Calgary, Calgary, Alberta, Canada 7Department of...
Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
Chronic hepatitis B (CHB) associated hepatocellular carcinoma (HCC) remains a significant global health concern, leading to significant morbidity and mortality. While most CHB patients undergo standard surveillance programmes, there is substantial research interest in developing predictive models to risk stratify patients and individualise surveillance schedules, as well as to support decision-making regarding the initiation of antiviral therapy [1, 2].
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
1 Introduction The safety of biologic therapies has been well documented in inflammatory bowel disease (IBD) patients without significant comorbidity; however, data pertaining to the safety of biologic therapies in high-risk patient subgroups such as solid organ transplant (SOT) recipients, remain comparatively limited given their exclusion from clinical trials [1].
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Get full text access Log in, subscribe or purchase for full access. References 1. Dong, C ∙ Metzger, M ∙ Holsbø, E ∙ et al. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis Aliment Pharmacol Ther. 2020; 51:8-33 2. Truelove, SC ∙ Witts, LJ Cortisone in ulcerative colitis; final report on a therapeutic trial BMJ. 1955; 2:1041-1048 3. Dinesen, LC ∙ Walsh, AJ ∙ Protic, MN ∙ et al. The pattern and outcome of acute severe colitis J Crohns Colitis. 2010; 4:431-437 4.
Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
We thank Dr. Chetwood et al for their interest in the DECIDER study1 and their comments.2 We agree that the use of first-line thioguanine is an interesting proposition, since it achieves clinical remission in patients who have not responded to, or are intolerant of, conventional thiopurines with or without combination allopurinol.3, 4 In the DECIDER study, we do not think a third arm for thioguanine use would have been feasible since this would have required a larger sample size, and since we...
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
We thank Dr. van Liere et al1, 2 for their editorial relating to our article. We did not collect data relating to prior thiopurine exposure for this study as it was initially planned that the cohort would only include thiopurine-naïve individuals. However, given concerns regarding difficulties with recruitment, the inclusion was broadened to initiating thiopurine therapy including thiopurine-exposed individuals. While prior thiopurine exposure was not captured, intolerances were.
Clinical trial: Combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)
1 INTRODUCTION Thiopurine are established therapies for the treatment of inflammatory bowel disease (IBD), both as monotherapy and in combination with anti-tumour necrosis factor alpha (anti-TNF) therapy.
Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug
Editors, We read with great interest the study by Bokemeyer et al1 investigating the clinical effectiveness of vedolizumab and anti-tumour necrosis factor (anti-TNF) agents for ulcerative colitis (UC) as part of a prospective non-interventional German registry study. The authors showed that, in biologic-naïve patients with UC, first-line vedolizumab had similar efficacy at 12 months as anti-TNF agents, but a higher rate of treatment persistence at 12 and 24 months.
The Effect of Aspirin Use on Incident Hepatocellular Carcinoma-An Updated Systematic Review and Meta-Analysis
Abstract : Simple Summary Aspirin has been observed to reduce the risk of developing hepatocellular carcinoma (HCC). This review pooled together the results of all available published studies and found that aspirin reduces the risk of HCC by around 30%. In patients with cirrhosis, this effect was not seen and, overall, patients treated with aspirin were at a higher risk of bleeding, as expected.
Hepatitis C virus in people with serious mental illness: An analysis of the care cascade at a tertiary health service with a pilot ‘identify and treat’ strategy
Original Article Michael Braude, Corresponding Author Clinical Academic Fellow mrh.braude@gmail.com orcid.org/0000-0002-6641-0032 Department of Gastroenterology and Hepatology, Monash Health, Melbourne, Australia School of Clinical Sciences, Monash University, Melbourne, Australia Correspondence Dr Michael Braude Department of Gastroenterology and Hepatology Monash Health Address: 246 Clayton Road, Clayton, Victoria, Australia, 3168 Email: mrh.braude@gmail.com Telephone: +61395943177 Fax:...
Hyperferritinaemia and iron overload in Asian patients: lessons from an Australian tertiary centre experience
Brief Communication Danny Con, Corresponding Author dannycon302@gmail.com orcid.org/0000-0002-4983-6103 Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia Correspondence Danny Con, Department of Gastroenterology, 3 West, Building B, Box Hill Hospital, 8 Arnold Street, Box Hill, Vic. 3128, Australia. Email: dannycon302@gmail.com Search for more papers by this author Amanda J.
Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors’ reply
INVITED EDITORIAL Abhinav Vasudevan Corresponding Author E-mail address: abhinav.vasudevan@monash.edu https://orcid.org/0000-0001-5026-9014 Department of Gastroenterology and Hepatology, Eastern Health Clinical School, Monash University, Victoria, Australia Search for more papers by this author PDF ShareShare Abstract LINKED CONTENT This article is linked to Vasudevan et al and Fraser papers.
Comparison of 48‐week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta‐analysis
ORIGINAL PAPER Ammar Majeed Department of Gastroenterology, Alfred Health, Melbourne, VIC, Australia Central Clinical School, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, VIC, Australia Search for more papers by this author Stuart Roberts https://orcid.org/0000-0002-9015-7997 Department of Gastroenterology, Alfred Health, Melbourne, VIC, Australia Central Clinical School, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, VIC,...
Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease
Summary Background There are safety concerns regarding immunomodulators (thiopurines and methotrexate) for treatment of inflammatory bowel disease (IBD). Aim To compare the long‐term tolerability, and persistence of thiopurine and methotrexate therapy in IBD. Methods A retrospective cohort study was performed at two hospitals between 1 January 2004 and 31 December 2016 for patients commenced on thiopurines or methotrexate for IBD.
Acute medical stabilisation of adults with Anorexia Nervosa - experience of a defined interdisciplinary model of care
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Original Article Acute medical stabilisation of adults with Anorexia Nervosa – experience of a defined interdisciplinary model of care Michael R.
Faecal calprotectin delivers on convenience, cost reduction and clinical decision making in inflammatory bowel disease: a real world cohort study
Faecal calprotectin (FC) is an accurate biomarker of disease activity in inflammatory bowel disease (IBD), yet the cost/resource implications of incorporating FC into ‘real world’ practice remain uncertain. To evaluate the utility of FC in clinical decision‐making and on healthcare costs in IBD.
Examination of the relationship between disease activity and patient reported outcome measures in an Inflammatory Bowel Disease cohort
The extent to which disease activity impacts on patient reported outcomes (PROs) is unclear. The purpose of this study was to examine the relationship between disease activity and PROs. Adult IBD patients attending a tertiary clinic from May to June 2015 were included.
Thunderstorm Asthma ‐ Revealing a hidden at‐risk population
To characterise the nature and extent of respiratory symptoms in healthcare workers during the Melbourne Thunderstorm Asthma event. A survey was conducted among staff and volunteers across Eastern Health, distributed on the intranet homepage, by e‐mail, and by word of mouth. Anonymous survey questions were constructed to assess prior and current diagnoses of relevance, symptoms, and demography.
Design considerations for an eHealth decision support tool in inflammatory bowel disease self-management
Electronic health (eHealth) decision support tools have the potential to: facilitate inflammatory bowel disease (IBD) self-management; reduce health care utilization, and; alleviate the pressure on over-burdened outpatient clinics. The purpose of this study was to explore the perspectives of key stakeholders on the potential use of a decision support tool for IBD patients.
Design considerations for an eHealth decision support tool in inflammatory bowel disease self‐management
Electronic health (eHealth) decision support tools have the potential to: facilitate inflammatory bowel disease (IBD) self‐management, reduce health care utilisation and alleviate the pressure on overburdened outpatient clinics. The purpose of this study was to explore the perspectives of key stakeholders on the potential use of a decision support tool for IBD patients.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Danny
Contact Danny, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack